Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration

References

• Witzig T, Dhodapkar M, Kyle R, . Quantification of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. Cancer 1993;72:108–113.
   PubMed Web of Science ®Google Scholar
• Witzig T, Gertz MA, Lust JA, . Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996;88:1780–1787.
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301–314.
   PubMed Web of Science ®Google Scholar
• Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60–66.
   PubMed Web of Science ®Google Scholar
• Bao H, Jiang M, Zhu M, . Overexpression of annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 2009;90:177–185.
   PubMed Web of Science ®Google Scholar
• Ullmannova-Benson V, Guan M, Zhou X, . DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 2009;23:383–390.
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943–1947.
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA, . Identification of a candidate tumor suppressor gene MMACI at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356–362.
   PubMed Web of Science ®Google Scholar
• Myers MP, Stolarov JP, Eng C, . PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphotase. Proc Natl Acad Sci USA 1997;94:9052–9057.
   PubMed Web of Science ®Google Scholar
• Dahia PL, Aguiar RC, Alberta J, . PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet 1999;8: 185–193.
   PubMed Web of Science ®Google Scholar
• Yilmaz OH, Valdez R, Theisen BK, . PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006;441:475–482.
   PubMed Web of Science ®Google Scholar
• Liu YL, Castleberry RP, Emanuel PD. PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leuk Res 2009;33:671–677.
   PubMed Web of Science ®Google Scholar
• Xu Q, Simpson SE, Scialla TJ, . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972–980.
   PubMed Web of Science ®Google Scholar
• Montiel-Duarte C, Cordeu L, Agirre X, . Resistance to imatinib mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. Leuk Res 2008;32:709–716.
   PubMed Web of Science ®Google Scholar
• Ge NL, Rudikoff S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene 2000;19:4091–4095.
   PubMed Web of Science ®Google Scholar
• Choi Y, Zhang J, Murga C, . PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002;21:5289–5300.
   PubMed Web of Science ®Google Scholar
• Sakai A, Thieblemont C, Wellmann A, . PTEN gene alterations in lymphoid neoplasms. Blood 1998;92:3410–3454.
   PubMed Web of Science ®Google Scholar
• Butler MP, Wang SI, Chaganati RSK, . Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer 1999;24:322–327.
   PubMed Web of Science ®Google Scholar
• Aggerholm A, Gronbaek K, Guldberg P, . Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol 2000;65:109–113.
   PubMed Web of Science ®Google Scholar
• Zhang J, Choi Y, Mavromatis B, . Preferential killing of PTEN-null myelomas by P13K inhibitors through Akt pathway. Oncogene 2003;22:6289–6295.
   PubMed Web of Science ®Google Scholar
• Hyun T, Yam A, Pece S, . Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000;96: 3560–3568.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi XY, Claudio J, . Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 2006;30:262–265.
   PubMed Web of Science ®Google Scholar
• Wang S, Cheng Z, Yang X, . Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma. Int J Hematol 2010;92:83–94.
   PubMed Web of Science ®Google Scholar
• Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol 1999;71:435–478.
   PubMed Web of Science ®Google Scholar
• Canel M, Secades P, Garzón-Arango M, . Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. Br J Cancer 2008;98:1274–1284.
   PubMed Web of Science ®Google Scholar
• Tamura M, Gu J, Danen EH, . PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 1999;274:20693–20703.
   PubMed Web of Science ®Google Scholar
• Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132: 410–451.
   PubMed Web of Science ®Google Scholar
• Cheng ZY, Guo XL, Yang XY, . PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res 2008,27:87.
   PubMed Web of Science ®Google Scholar
• Zhang J, Grindley JC, Yin T, . PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006;441:518–522.
   PubMed Web of Science ®Google Scholar
• Gauffin F, Diffner E, Gustafsson B, . Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic leukemia. Pediatr Hematol Oncol 2009;26:48–56.
   PubMed Web of Science ®Google Scholar
• Silva A, Yunes JA, Cardoso BA, . PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 2008,118:3762–3774.
   PubMed Web of Science ®Google Scholar
• Shi Y, Gera J, Hu L, . Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62: 5027–5034.
   PubMed Web of Science ®Google Scholar
• Pene F, Claessens YE, Muller O, . Role of the phosphatidylinositol 3-kinase/AKT and mTOR/P70S6-kinase pathways in the prolifer ation and apoptosis in multiple myeloma. Oncogene 2002;21: 6587–6597.
   PubMed Web of Science ®Google Scholar
• Li J, Xiong WJ, Luo SK, . Expression of PTEN mRNA in mononuclear cells of bone marrow of multiple myeloma. Chin J Clin Oncol Rehabil 2004;11:398–400.
   Google Scholar
• McCampbell AS, Broaddus RR, Loose DS, . Overexpression of the insulin-like growth factor I receptor and activation of the AKT path way in hyperplastic endometrium. Clin Cancer Res 2006;12:6373–6378.
   PubMed Web of Science ®Google Scholar
• Kotelevets L, van Hengel J, Bruyneel E, . The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J Cell Biol 2001;155:1129–1135.
   PubMed Web of Science ®Google Scholar
• Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004;14:92–101.
   PubMed Web of Science ®Google Scholar
• Haier J, Nicolson GL. PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow. Oncogene 2002,21:1450–1460.
   PubMed Web of Science ®Google Scholar